

## **South Carolina Statistics** PCSK9 Inhibitors

South Carolina patients' access to PCSK9 inhibitors can vary widely depending upon whether their coverage is commercial or Medicare.

$\square$	Initial Rejection Rates		<b>₽</b> ×	Final Rejection Rates	
	Commercial: <b>72%</b>	Medicare:		Commercial: <b>59%</b>	Medicare: <b>15%</b>

The table below highlights the rejection rates for South Carolina insurers who provide both commercial and Medicare coverage.

Health Plan	Total Claims	Initial Rejections	Final Rejections	
Aetna	Commercial	84	42%	24%
Aetria	Medicare	262	29%	8%
Blue Cross Blue Shield of	Commercial	195	76%	70%
South Carolina	Medicare	98	37%	17%
Ciana Haaltheara	Commercial	108	30%	18%
Cigna Healthcare	Medicare	76	49%	16%
CVS Health	Commercial	113	96%	94%
CVS Health	Medicare	265	49%	17%
South Carolina Public	Commercial	101	97%	82%
Employee Benefit Authority	Medicare	325	40%	16%
United Health Crown	Commercial	68	69%	56%
United Health Group	Medicare	629	48%	21%

Source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017

